So, this suggests the clinical efficacy of periodic monitoring of emerging or rising ESR1 mutations in ctDNA to trigger an early change from an aromatase inhibitor plus palbociclib to fulvestrant plus palbociclib treatment in patients with rising circulating ESR1 mutations detected even without tumor progression. Here, CYP19A1 is linked to neoplasm.